Get started
Anavex Life Sciences Corp.Anavex Life Sciences Corp.Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

AVXL trade ideas

$AVXL is gonna fall todayPupm&Dump trading strategy idea. $AVXL is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $23,49; stop-loss — $24,55; take-profit — $21,37. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:AVXLShort
by KozakHlib
AVXL Week 12/07/21 - 17/07/21. It is my first public analysis after having a dozen or so or private and correct analysis. I believe however I need to disclose I am not a financial advisor, however I am a investor in several of AVXL positions and have been studying this stock for a while. Anyways, in y analysis I came to spot the formation of the first smaller cup, and fibonacci regressions to predict accurately the last peak of the AVXL stock. Furthermore, in the current down correction of the market, with still strong buy technicals came to spot the formation and current development of a larger, rather shallow second upwards cup; in white. measuring and using the fundamentals values of the last 3 AVXL formations I predict the formation of a handle. bottom at the range of the dotted and solid red lines, price consolidation should happened between $24.04 - $24.62. before carrying on its upwards trend hitting the $28- $28.15 mark. depending on the height in relation to the last price peak on 9th of July which should see a new price consolidation range of roughly $28.3-$27.1 before breaking upwards in the magnitude of 410px -420px. from the this new base price, a conservative calculated peak of $29.6 but possibly as high as $32. Important to note would be whether AVXL has the ability of break the previous highest resistance level of $29.65 - 31.5. Failing to do so we could possibly see a big market reversal. plummeting AVXL to the previous base price of $20-21.5 within next week before trying to break this ceiling once gain. On the other side of the spectrum. Breaking the $31.5 resistance is unlikely to maintain these gains due to no changed fundamentals, but it would solidly the new support price at $27.2 - $27.9 and a solid base price at $25.2. before seeing further advancing into my predicted $35-33 Price consolidation at market optimal point before a change in fundamentals. This is in the form of the success of their clinical trials and pending FDA approvals, which, if continues the positive trend could see this company valuation triple over the course of a few days and its stock value (under current float outstanding) easily reach pass the 80-90 dollar mark.
NASDAQ:AVXLLong
by suikaking
Sympathy playSympathy play Anavex stock gained after favorable data from Cassava Sciences in Alzheimer’s! With a rise yesterday, Cassava Sciences extended its gains after announcement of favorable data from an open-label study in Alzheimer’s disease! The shares have been on a bullish mode for the last several days, reaching an all-time high, on encouraging data for its differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders such as Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system diseases.
NASDAQ:AVXL
by AlenCiken
2
Anavex Life Sciences Corp. on Breakout Alert Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. Short interest 12% Buy rating | $12 analysts average target
NASDAQ:AVXLLong
by DEXWireNews
Anavex Life Science setting up for Bull run Phase 2 Data Anavex Life Sciences is up on almost 50% higher volume in reaction to the results from a study evaluating the gut microbiota of Alzheimer's patients enrolled in its Phase 2a extension study of ANAVEX 2-73. The analysis showed that patients receiving ANAVEX 2-73, a sigma-1 receptor (S1R) agonist, had high levels of two gut microbiota families that were associated with improved daily living activities at week 148. CEO Christopher Missling, Ph.D. says, “This is the first gut microbiota DNA sequencing analysis of Alzheimer’s disease patients treated with ANAVEX 2-73 which might help to identify potential biomarkers of response for ANAVEX 2-73. We continue to advance the ANAVEX 2-73 Alzheimer’s disease program through the ongoing Phase 2b/3 Alzheimer’s disease clinical study and in other ongoing ANAVEX 2-73 clinical trials focused on serious neurology diseases with high unmet needs, including Rett syndrome and Parkinson’s disease dementia.” Source Seeking Alpha. AVERAGE ANALYSTS PRICE TARGET $10 AVERAGE ANALYSTS RECOMMENDATION BUY P/E RATIO SHORT INTEREST 9% COMPANY PROFILE Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
NASDAQ:AVXLLong
by DEXWireNews
1